Search results

  1. E

    Genetic and functional analysis of Raynaud’s syndrome implicates loci in vasculature and immunity 2024 Tervi et al

    Seems to be the published version of The alpha-2A-adrenergic receptor (ADRA2A) modulates susceptibility to Raynaud's syndrome? They note that Raynauds is a common comorbidity in Long-Covid and ME/CFS (they cite https://www.tandfonline.com/doi/abs/10.1080/10852352.2014.973240). I've seen this...
  2. E

    What research do you want to see? (study ideas)

    In which case it's clearly not a priority since they've been sitting on this data for years. I wonder whether they will match controls and patients, since he somehow had a problem with that and I wasn't able to understand his argument.
  3. E

    What research do you want to see? (study ideas)

    I agree. The question to me however is whether more 2-day CPET studies will really lead us to understanding anything about more pathology. Because several 2-day CPET studies have been published, thousands of patients have gone through the procedure and Workwell has data on several hundreds of...
  4. E

    Blood transcriptomics reveal persistent SARS-CoV-2 RNA and candidate biomarkers in Long COVID patients, 2024, Menezes et al.

    The LCAP has a very bad reputation and is extremely controversial. I'm also not sure what half of the stuff they are saying is supposed to mean for example "with help from out grassroots activism", does that just mean you're collecting money for this research project and giving it to these...
  5. E

    Blood transcriptomics reveal persistent SARS-CoV-2 RNA and candidate biomarkers in Long COVID patients, 2024, Menezes et al.

    From what I've heard they've already looked at this tests in independent cohorts and the success has been rather variable. Controlling for reinfections and quantifing data according to LC duration and date of last known infection will be key for any Long-Covid "viral-persistence markers".
  6. E

    Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome, 2024, Walitt et al

    I think so. It seems to all be included in the "Neurophysiology Data Files".
  7. E

    Metformin

    The thing I enjoyed is that Caroline Bramante, the principal investigator of the Metformin trials, seems to be very open with the fact that they do not know whether it works at all and that they cannot be certain that it works via antiviral effects (for LC). In fact I remember her saying in a...
  8. E

    Metformin

    Certainty of evidence: Very low. I can only agree with that. Still don't understand why they only used overweight people which could bias any results towards Metformin or why Ivermectin was used in the first place. With that many different treatments I don't even know, were the studies actually...
  9. E

    Trial Report Blood Flow To The Head Is Reduced in a Patient With Myalgic Encephalomyelitis With Confirmed Post-Exertional Malaise, 2024, Lee

    Poster presentations are generally because the quality of content is not sufficient to justify a proper talk, because you are a junior researcher or simply because you aren't friendly with the right people that would give you the space for a proper talk. It's about spreading the word and putting...
  10. E

    Trial Report Blood Flow To The Head Is Reduced in a Patient With Myalgic Encephalomyelitis With Confirmed Post-Exertional Malaise, 2024, Lee

    Seems to be a poster so presumably the work someone does in a bachelor or master thesis to learn how to do things, rather than publishing something meaningful.
  11. E

    When would a GWAS study help disprove the belief that ME/CFS is psychological

    From what I’ve understood the strengths of a GWAS study is that it reflects causes rather than effects of an illness as genes don’t change after ME onset. At what point can one conclude that a cause seems to be biological? From what I can see there have been several studies on conditions...
  12. E

    Financial Outcome Measure

    Whilst I see your point and see it similar, I'm not sure everyone would have the same depth in view as you. I think many politicians or people being addressed will simply think: This diseases affects many people of working age and so and so many billions are lost, so that is a convincing...
  13. E

    Blood Neurofilament Light Chain: The Neurologist’s Troponin?, 2020, Thebault et al

    This little table, taken from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198337/ seems quite useful as it summarizes the current research on NfL for different diseases. Similarly this table shows that there is a large overlap between healthy controls and different illnesses. There is also an...
  14. E

    Infection and chronic disease activate a systemic brain-muscle signaling axis, 2024, Johnson et al

    At least according to the study. But then again I don't even know, maybe this has always been well known in humans as well?
  15. E

    Infection and chronic disease activate a systemic brain-muscle signaling axis, 2024, Johnson et al

    Infection and chronic disease activate a systemic brain-muscle signaling axis Editor’s summary Neuroinflammation can cause symptoms outside of the central nervous system (CNS), including muscle pain and fatigue, yet how inflammatory signals in the brain are communicated to muscle remains to be...
  16. E

    Grip test results and brain imaging in the NIH study: Deep phenotyping of PI-ME/CFS, 2024, Walitt et al

    The fact that one number is off an additional order of magnitude than the other one suggest that either something else is going on which cannot be corrected by taking the relative rate (i.e. doing something like the taking difference of these values diving by initial value and multiplying by...
  17. E

    Grip test results and brain imaging in the NIH study: Deep phenotyping of PI-ME/CFS, 2024, Walitt et al

    Do you know whether the Dimitrov index has been validated. The thread on the original study suggests it wasn't validated at the time and I'm wandering whether that has changed?
  18. E

    Efgartigimod (Vyvgart) - what could the trial data possibly tell us?

    I don't think this is news. The trial has always had an open label extension arm (see post above). The information is still that the trial flunked and future investigations are cancelled. I think they have no rush to release any data, because that is in no way beneficial to them.
  19. E

    Interferon subverts an AHR–JUN axis to promote CXCL13+ T cells in lupus, 2024, Law et al.

    I don’t have access to the paper but the story they are telling seems to be: Interferons cause a deficiency in AHR Receptor Ligands. Without as much AHR Receptor Ligands you then get more bad T cells that call for more bad B cells. Once they reintroduced the AHR-activating molecules to blood...
Back
Top Bottom